Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can family support ease the burden of advanced lung cancer?

NCT ID NCT07490639

Symptom relief Sponsor: Shanxi Province Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a family-supported palliative care program could improve quality of life and emotional well-being in 110 people with advanced lung cancer. Participants were randomly assigned to either the family-supported program or standard nursing care for 8 weeks. The program included education, caregiver training, and emotional support, aiming to reduce anxiety and help with decision-making.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Family-Supported Palliative Care (behavioral intervention)
What this could lead to
If successful, this approach could provide a structured way to improve quality of life and emotional well-being for people with advanced lung cancer through family involvement.
What could go wrong
This is a small, single-center study with no blinding, so results may not apply broadly. The intervention is behavioral, not a drug, so benefits may be modest and hard to replicate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

110 people

The number who actually took part.

Started

Jan 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pathologically or cytologically confirmed diagnosis of advanced lung cancer (stage III-IV or limited prognosis). * Age ≥ 18 years. * Receiving initial or first-line systemic treatment. * Fully informed of the diagnosis, with normal cognitive function and ability to communicate effectively. * Able to complete questionnaires and assessments. * Provided written informed consent. Exclusion Criteria: * Prior exposure to more than one line of systemic antitumor therapy. * Severe cognitive impairment or diagnosed psychiatric disorders affecting compliance. * Severe comorbid conditions (cardiac, hepatic, or renal dysfunction) with life expectancy \< 3 months. * Conditions that may interfere with outcome assessment, such as active infection or systemic inflammatory diseases.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung carcinoma lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced lung cancer Lung neoplasms Non-small cell lung cancer

Contacts and locations

Locations

  • Shanxi Province Cancer Hospital

    Taiyuan, Shanxi, 030013, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.